Evidence map›Paper›PMID 22662208›Full record

ArticlePloS one2012

Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.

Syed M Meeran, Shweta N Patel, Yuanyuan Li, Samriddhi Shukla, Trygve O Tollefsbol

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 116 citations in OpenAlex.

  1. Review
  2. Cancer and Traditional Medicine: An Integrative Approach.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Novel molecules as the emerging trends in cancer treatment: an update.Medical oncology (Northwood, London, England) · 2022
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Syed M MeeranDivision of Endocrinology, CSIR-Central Drug Research Institute, Lucknow, India. s.musthapa@cdri.res.in
Shweta N Patel
Yuanyuan Li
Samriddhi Shukla
Trygve O Tollefsbol
University of Alabama at Birmingham · USCentral Drug Research Institute · IN

Funding

Epigenetics of Tea Polyphenols in Cancer PreventionR01CA129415 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2008 to 2011
$956k
NCI NIH HHS R01 CA129415
6 · The paper itself

Abstract

Breast cancer is the most common cancer and the leading cause of cancer death in women. Although tamoxifen therapy is successful for some patients, it does not provide adequate benefit for those who have estrogen receptor (ER)-negative cancers. Therefore, we approached novel treatment strategies by combining two potential bioactive dietary supplements for the reactivation of ERα expression for effective treatment of ERα-negative breast cancer with tamoxifen. Bioactive dietary supplements such as green tea polyphenols (GTPs) and sulforaphane (SFN) inhibit DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), respectively, which are of central importance to cancer prevention. In the present study, we have observed that treatment of ERα-negative breast cancer cells with GTPs and SFN alone or in combination leads to the reactivation of ERα expression. The combination of 20 µg/mL GTPs and 5 µM SFN was found to be the optimal dose of ERα-reactivation at 3 days in MDA-MB-231 cells. The reactivation of ERα expression was consistently correlated with ERα promoter hypomethylation and hyperacetylation. Chromatin immunoprecipitation (ChIP) analysis of the ERα promoter revealed that GTPs and SFN altered the binding of ERα-transcriptional co-repressor complex thereby contributing to ERα-reactivation. In addition, treatment with tamoxifen in combination with GTPs and SFN significantly increased both cell death and inhibition of cellular proliferation in MDA-MB-231 cells in comparison to treatment with tamoxifen alone. Collectively, our findings suggest that a novel combination of bioactive-HDAC inhibitors with bioactive-demethylating agents is a promising strategy for the effective treatment of hormonal refractory breast cancer with available anti-estrogens.

Indexed as

Dietary SupplementsBreast NeoplasmsCell Line, TumorCell ProliferationChromatinDNA MethylationDrug SynergismEpigenesis, GeneticEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHistonesHumansIsothiocyanatesPlant ExtractsChromatinEstrogen Receptor alphaHistone Deacetylase InhibitorsHistonesIsothiocyanatesPlant ExtractsPolyphenolsReceptors, EstrogenSelective Estrogen Receptor ModulatorssulforaphaneSulfoxidesTeaThiocyanatesTranscription Factors

Identifiers

PMID22662208
PMCPMC3360625
OpenAlexW2106788905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.